{"filing":{"accession_number":"0001193125-26-399416","cik":"0000873303","ticker":"SRPT","company_name":"Sarepta Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-23","report_date":"2026-09-23","primary_document":"srpt-20260923.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/873303/000119312526399416/srpt-20260923.htm"},"events":[{"id":34588,"run_id":31832,"accession_number":"0001193125-26-399416","anchor_item_number":"1.01","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"summary":"The filing discloses settlement of material patent infringement litigations involving Sarepta's gene therapy product ELEVIDYS and UPenn Patents. The Company had already recorded a $39.0 million litigation contingency charge in Q2 2026, and the settlement agreement resolves pending patent infringement claims and inter partes review proceedings with a $39.0 million payment to REGENXBIO, plus a covenant not to sue regarding AAVrh74-based capsid products. This is a material litigation settlement that would affect investor assessment of the registrant's patent position and product commercialization risk.","company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","filing_date":"2026-09-23","form":"8-K","submitted_at":null,"items":[{"id":38349,"accession_number":"0001193125-26-399416","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"reasoning":"The filing discloses settlement of material patent infringement litigations involving Sarepta's gene therapy product ELEVIDYS and UPenn Patents. The Company had already recorded a $39.0 million litigation contingency charge in Q2 2026, and the settlement agreement resolves pending patent infringement claims and inter partes review proceedings with a $39.0 million payment to REGENXBIO, plus a covenant not to sue regarding AAVrh74-based capsid products. This is a material litigation settlement that would affect investor assessment of the registrant's patent position and product commercialization risk.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T20:18:43.760958+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38349,"accession_number":"0001193125-26-399416","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"reasoning":"The filing discloses settlement of material patent infringement litigations involving Sarepta's gene therapy product ELEVIDYS and UPenn Patents. The Company had already recorded a $39.0 million litigation contingency charge in Q2 2026, and the settlement agreement resolves pending patent infringement claims and inter partes review proceedings with a $39.0 million payment to REGENXBIO, plus a covenant not to sue regarding AAVrh74-based capsid products. This is a material litigation settlement that would affect investor assessment of the registrant's patent position and product commercialization risk.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T20:18:43.760958+00:00","company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","filing_date":"2026-09-23"}]}